In Depth Analysis

This +Insight aims to make sense of the various activities and proposals underway or under consideration that could impact drug prices paid by consumers.

Our latest +Insight breaks down what CMS finalized, where the pressure points are, and what stakeholders should be weighing as they consider participation.

Explore key health-related provisions in the recently passed FY 2026 minibus.

This +Insight highlights the key legislative and administrative developments to watch – from affordability and coverage debates to Medicare, Medicaid, drug pricing, digital health, and innovation initiatives moving through federal agencies. Read on to learn why these developments matter now, and how they could influence planning, compliance, and strategic decision-making in 2026 and beyond.